Equities

Fluicell AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Fluicell AB

Actions
  • Price (SEK)9.45
  • Today's Change0.000 / 0.00%
  • Shares traded9.45k
  • 1 Year change-44.44%
  • Beta0.9342
Data delayed at least 15 minutes, as of Feb 09 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

  • Revenue in SEK (TTM)2.68m
  • Net income in SEK-9.86m
  • Incorporated2012
  • Employees11.00
  • Location
    Fluicell ABFlojelbergsgatan 8CMOELNDAL 431 37SwedenSWE
  • Phone+46 313607481
  • Websitehttps://fluicell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PCI Biotech Holding ASA4.37m-19.12m6.73m7.00--0.5771--1.54-0.5502-0.55020.12560.33530.1676--0.896669,714.30-73.44-41.44-92.22-46.61-----438.10-897.91----0.022--125.25-6.4319.19------
Lidds AB0.00-5.58m6.82m1.00--4.57-----0.0409-0.04090.000.01090.00----0.00-99.68-64.76-119.64-76.72---1,554.86---2,637.08----0.00------85.23---65.39--
Stayble Therapeutics AB0.00-8.42m12.60m2.00--1.49-----0.168-0.1680.000.13140.00----0.00-78.98-78.82-83.99-92.78------------0.0913------47.69------
Respiratorius AB (publ)0.00-7.12m12.68m----0.3929-----1.30-1.300.004.090.00-------21.57---22.10-------------133.510.00------3.36---32.52--
Fluicell AB2.68m-9.86m12.98m11.00--1.20--4.84-7.18-7.181.957.860.1257-2.793.22268,100.00-46.21-89.03-62.52-133.15428.8786.83-367.74-656.390.6057--0.00---44.31-5.6641.59--33.86--
Gabather AB0.00-4.65m14.75m2.00---------0.0384-0.03840.00-0.01110.00----0.00-209.07-67.13---90.59-----------76.57--------17.84------
Novakand Pharma AB0.00-51.90m15.75m5.00--0.7865-----0.4283-0.42830.000.16530.00----0.00-103.07-54.11-112.87-63.47--70.00---275,694.40----0.00------31.32------
ATTANA AB4.10m-12.78m20.64m6.00--0.6084--5.03-0.0154-0.01540.00470.01320.1425-0.76111.02656,600.00-44.37-37.91-61.34-48.09161.16189.23-311.34-305.500.6079-3.790.1315---18.77-8.697.33--8.51--
Lumito AB (publ)81.51k-48.06m27.53m8.00--0.1986--337.72-20.16-20.160.025340.270.0008-0.42240.07916,792.50-47.58-24.12-62.09-26.46546.44---58,966.97-138,894.000.2668-22.920.1994-------61.08---30.66--
Aptahem AB0.00-7.43m28.37m----0.2308-----0.6711-0.67110.003.770.00-------11.21-30.70-11.57-34.24-----------44.150.00------22.90--88.99--
Data as of Feb 09 2026. Currency figures normalised to Fluicell AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.